OBJECTIVE: C-Reactive Protein (CRP), a nonspecific marker of inflammation that is moderately elevated in obesity, metabolic syndrome (MS), and type 2 diabetes, has been proposed as a surrogate marker of nonalcoholic steatohepatitis (NASH). Its clinical usefulness in the diagnosis of NASH was evaluated in severely obese patients without or with MS, diabetes, and NASH and the potential roles of the liver and of the adipose tissue in CRP production were characterized. METHODS: Severely obese patients without NASH (without MS [N = 13], with MS [N = 11], or with MS and diabetes [N = 7]) and with NASH (without [N = 8] or with [N = 7] MS) were studied. For each patient, liver and adipose tissue biopsies were collected during a bariatric surgery and were used to determine the CRP gene expression by real-time PCR. The role of interleukin-6 (IL6) and lipopolysaccharide in CRP expression was also evaluated in subcutaneous adipose tissue obtained during cosmetic abdominoplasty. RESULTS: Plasma CRP levels were elevated in severely obese patients independently from the presence or absence of MS, diabetes, or NASH. CRP gene expression was not only increased in livers but also in adipose tissues of obese patients compared with controls subjects. In human adipose tissue, CRP mRNA levels were positively correlated with those of IL-6 and the CRP expression was enhanced in vitro by IL-6 and lipopolysaccharide. CONCLUSION: Plasma CRP levels are not predictive of the diagnosis of NASH in severely obese patients. The liver but also the adipose tissue can produce CRP, a process which could be dependent on IL6. Therefore, both tissues might contribute to the elevated plasma CRP levels found in obesity. In addition, the large amount of body fat may well produce an important part of the circulating CRP, further limiting its clinical usefulness in the evaluation of NASH in severely obese patients.
OBJECTIVE:C-Reactive Protein (CRP), a nonspecific marker of inflammation that is moderately elevated in obesity, metabolic syndrome (MS), and type 2 diabetes, has been proposed as a surrogate marker of nonalcoholic steatohepatitis (NASH). Its clinical usefulness in the diagnosis of NASH was evaluated in severely obesepatients without or with MS, diabetes, and NASH and the potential roles of the liver and of the adipose tissue in CRP production were characterized. METHODS: Severely obesepatients without NASH (without MS [N = 13], with MS [N = 11], or with MS and diabetes [N = 7]) and with NASH (without [N = 8] or with [N = 7] MS) were studied. For each patient, liver and adipose tissue biopsies were collected during a bariatric surgery and were used to determine the CRP gene expression by real-time PCR. The role of interleukin-6 (IL6) and lipopolysaccharide in CRP expression was also evaluated in subcutaneous adipose tissue obtained during cosmetic abdominoplasty. RESULTS: Plasma CRP levels were elevated in severely obesepatients independently from the presence or absence of MS, diabetes, or NASH. CRP gene expression was not only increased in livers but also in adipose tissues of obesepatients compared with controls subjects. In human adipose tissue, CRP mRNA levels were positively correlated with those of IL-6 and the CRP expression was enhanced in vitro by IL-6 and lipopolysaccharide. CONCLUSION: Plasma CRP levels are not predictive of the diagnosis of NASH in severely obesepatients. The liver but also the adipose tissue can produce CRP, a process which could be dependent on IL6. Therefore, both tissues might contribute to the elevated plasma CRP levels found in obesity. In addition, the large amount of body fat may well produce an important part of the circulating CRP, further limiting its clinical usefulness in the evaluation of NASH in severely obesepatients.
Authors: Thomas R Magee; Guang Han; Bindu Cherian; Omid Khorram; Michael G Ross; Mina Desai Journal: Am J Obstet Gynecol Date: 2008-07-29 Impact factor: 8.661
Authors: Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò Journal: World J Cardiol Date: 2014-07-26
Authors: Brianna F Moore; Katherine A Sauder; Anne P Starling; James R Hébert; Nitin Shivappa; Brandy M Ringham; Deborah H Glueck; Dana Dabelea Journal: J Pediatr Date: 2017-12-06 Impact factor: 4.406
Authors: Bertha L Bullen; Nicole M Jones; Claudia B Holzman; Yan Tian; Patricia K Senagore; Poul Thorsen; Kristin Skogstrand; David M Hougaard; Alla Sikorskii Journal: Reprod Sci Date: 2012-12-07 Impact factor: 3.060
Authors: L Maria Belalcazar; David M Reboussin; Steven M Haffner; Ron C Hoogeveen; Andrea M Kriska; Dawn C Schwenke; Russell P Tracy; F Xavier Pi-Sunyer; Christie M Ballantyne Journal: Diabetes Care Date: 2010-08-03 Impact factor: 19.112
Authors: Adeline Bertola; Vanessa Deveaux; Stéphanie Bonnafous; Déborah Rousseau; Rodolphe Anty; Abdelilah Wakkach; Moncef Dahman; Joan Tordjman; Karine Clément; Siobhán E McQuaid; Keith N Frayn; Pierre-Michel Huet; Jean Gugenheim; Sophie Lotersztajn; Yannick Le Marchand-Brustel; Albert Tran; Philippe Gual Journal: Diabetes Date: 2008-10-24 Impact factor: 9.461